Revenue
No reported data
Dogwood Therapeutics, Inc. (DWTX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $21.9M | $3.5M | $1.7M | $8.1M | $10.8M | $194,013 |
| Operating expenses | $28.0M | $12.2M | $5.4M | $12.3M | $15.6M | $10.0M |
| Operating income | −$28.0M | −$12.2M | −$5.4M | −$12.3M | −$15.6M | −$10.0M |
| Net income | −$34.3M | −$12.3M | −$5.3M | −$12.2M | −$16.0M | −$10.3M |
| Basic EPSper diluted share | -$7.13 | -$12.52 | -$7.05 | -$1.11 | -$1.92 | -$2.10 |
| Diluted EPSper diluted share | -$7.13 | -$12.52 | -$7.05 | -$1.11 | -$1.92 | -$2.10 |